A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

NG-350A received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a significant unmet need in treatment options. Imfinzi combined with FLOT ...

Many patients with locally advanced rectal cancer treated with total neoadjuvant therapy in the OPRA trial achieved a complete or near-complete tumor response and were initially offered a ...

Sixteen patients with mismatch repair–deficient, locally advanced rectal cancer were enrolled in a pilot study in which 6 months of neoadjuvant anti–PD-1 therapy was to be followed by surgical ...

Among patients with locally advanced rectal cancer, concurrent chemoradiotherapy did not significantly increase second pelvic malignancies compared to chemotherapy alone, but it did raise the risk for ...

Colorectal cancer is one of the most prevalent tumors and a leading cause of cancer-related mortality. Despite advances achieved in recent years, resistance to available treatments remains one of the ...

Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...

Organ-sparing treatments offer alternatives to surgery, preserving quality of life for patients with specific genetic mutations in cancers like rectal and bladder cancer. Clinical trials with immune ...